calendar
18,993 catalysts · 18,987 approval · 5,347 phase readout · 5,000 device 510k · 4,728 grant · 2,603 8k filing · 2,000 device pma
18,993 catalysts · 18,987 approval · 5,347 phase readout · 5,000 device 510k · 4,728 grant · 2,603 8k filing · 2,000 device pma
Sponsor: GLAXOSMITHKLINE LLC. Form: TABLET. Route: ORAL
Sponsor: GLAXOSMITHKLINE LLC. Form: TABLET, FOR SUSPENSION. Route: ORAL
Sponsor: GLAXOSMITHKLINE LLC. Form: TABLET, FOR SUSPENSION. Route: ORAL
Sponsor: GLAXOSMITHKLINE LLC. Form: TABLET, EXTENDED RELEASE. Route: ORAL
Sponsor: GLAXOSMITHKLINE LLC. Form: TABLET, EXTENDED RELEASE. Route: ORAL
Sponsor: CHARTWELL MOLECULAR. Form: SOLUTION. Route: ORAL
Sponsor: COLLEGIUM PHARM INC. Form: TABLET. Route: ORAL
Sponsor: SANOFI AVENTIS US. Form: INJECTABLE. Route: INJECTION
Sponsor: PURDUE PHARMA LP. Form: TABLET, EXTENDED RELEASE. Route: ORAL
Sponsor: SUN PHARM INDS INC. Form: TABLET. Route: ORAL
Sponsor: DR REDDYS LABS LTD. Form: TABLET. Route: ORAL
Sponsor: AUROBINDO PHARMA. Form: TABLET, ORALLY DISINTEGRATING. Route: ORAL
Sponsor: ACTAVIS ELIZABETH. Form: TABLET, EXTENDED RELEASE. Route: ORAL
Sponsor: SANDOZ. Form: TABLET, ORALLY DISINTEGRATING. Route: ORAL
Sponsor: NATCO. Form: TABLET. Route: ORAL
Sponsor: COLLEGIUM PHARM INC. Form: TABLET. Route: ORAL
Sponsor: BAYER. Form: TABLET. Route: ORAL
Sponsor: AUROBINDO PHARMA. Form: TABLET. Route: ORAL
Sponsor: SANOFI AVENTIS US. Form: CAPSULE. Route: ORAL
Sponsor: TAKEDA PHARMS USA. Form: CAPSULE. Route: ORAL
Sponsor: TAKEDA PHARMS USA. Form: CAPSULE. Route: ORAL
Sponsor: TAKEDA PHARMS USA. Form: CAPSULE. Route: ORAL
Sponsor: TAKEDA PHARMS USA. Form: CAPSULE. Route: ORAL
Sponsor: SANOFI AVENTIS US. Form: TABLET. Route: ORAL
Sponsor: TAKEDA PHARMS USA. Form: CAPSULE, EXTENDED RELEASE. Route: ORAL
Sponsor: TAKEDA PHARMS USA. Form: CAPSULE, EXTENDED RELEASE. Route: ORAL
Sponsor: SANDOZ. Form: CAPSULE, EXTENDED RELEASE. Route: ORAL
Sponsor: SANDOZ. Form: CAPSULE, EXTENDED RELEASE. Route: ORAL
Sponsor: HIKMA. Form: TABLET. Route: ORAL
Sponsor: ANI PHARMS. Form: TABLET. Route: ORAL
Sponsor: HIKMA. Form: INJECTABLE. Route: INJECTION
Sponsor: IMMUNEX. Form: SYRINGE
Sponsor: HIKMA INTL PHARMS. Form: CAPSULE. Route: ORAL
Sponsor: ABBVIE INC. Form: VIAL
Sponsor: MICRO LABS. Form: CAPSULE. Route: ORAL
Sponsor: PF PRISM CV. Form: TABLET. Route: ORAL
Sponsor: PF PRISM CV. Form: POWDER. Route: INTRAVENOUS
Sponsor: PF PRISM CV. Form: FOR SUSPENSION. Route: ORAL
Sponsor: TEVA. Form: TABLET. Route: ORAL
Sponsor: JANSSEN PHARMS. Form: TABLET, EXTENDED RELEASE. Route: ORAL
Sponsor: JANSSEN PHARMS. Form: TABLET, EXTENDED RELEASE. Route: ORAL
Sponsor: CHEPLAPHARM. Form: TABLET, ORALLY DISINTEGRATING. Route: ORAL
Sponsor: CHEPLAPHARM. Form: SUSPENSION, EXTENDED RELEASE. Route: INTRAMUSCULAR
Sponsor: CHEPLAPHARM. Form: TABLET. Route: ORAL
Sponsor: CHEPLAPHARM. Form: POWDER. Route: INTRAMUSCULAR
Sponsor: JANSSEN PHARMS. Form: INJECTABLE. Route: INJECTION
Sponsor: SANDOZ. Form: CAPSULE, EXTENDED RELEASE. Route: ORAL
Sponsor: SPECGX LLC. Form: TABLET, EXTENDED RELEASE. Route: ORAL
Sponsor: PF PRISM CV. Form: TABLET. Route: ORAL
Sponsor: PF PRISM CV. Form: TABLET. Route: ORAL